Daniel Ives

May 28, 2026

Daniel Ives rated SNOW as Outperform on May 28, 2026, setting a price target of 280. The call has proven timely, with shares rising 37.84% toward the price target of 280.

May 27, 2026

On May 27, 2026, PANW was given a Outperform rating by Daniel Ives, with a target price of 300. The stock rallied 36.23% after the rating, narrowing the gap to the target of 300 and validating the bullish stance.

May 27, 2026

CRWD received a Outperform rating from Daniel Ives on May 27, 2026, aiming for 700. Momentum has favored the Buy call, with shares climbing from 208.86 to 208.86, rewarding those who trusted the recommendation.

May 13, 2026

On May 13, 2026, Daniel Ives published a Outperform outlook on ORCL, with a target of 275. Market action contradicted the Buy thesis, as shares slipped to 153.17.

Apr 29, 2026

Daniel Ives on Apr 29, 2026 assigned VRNS a Outperform rating, with a price target of 37. The Buy call aligned well with market performance, producing a gain of 66.73%.

Apr 17, 2026

On Apr 17, 2026, Daniel Ives reaffirmed IBM with a Outperform rating, targeting 340. Shares slid 7.67% despite the recommendation, highlighting downside risks.

Apr 09, 2026

WLDN was rated Outperform by Daniel Ives on Apr 09, 2026, with a price objective of 110. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Mar 27, 2026

On Mar 27, 2026, Daniel Ives initiated coverage on AAPL with a Outperform rating and target of 350. The stock’s climb of 31.26% since the call highlights the foresight in the rating.

Mar 03, 2026

Daniel Ives issued a Outperform recommendation for MDB on Mar 03, 2026, price target set at 440. Investors following the Buy call captured upside momentum, with shares now at 373.87.

Jan 30, 2026

On Jan 30, 2026, INOD was evaluated by Daniel Ives, who gave a Outperform rating and target of 90. So far, the Buy call awaits clearer momentum, with shares flat at 53.11.

Jan 13, 2026

Daniel Ives rated PL as Outperform on Jan 13, 2026, setting a price target of 28. The stock has underperformed, dropping 34.08% despite the bullish target of 28.

Dec 22, 2025

On Dec 22, 2025, MSFT was given a Outperform rating by Daniel Ives, with a target price of 625. The stock traded sideways with a 1.55% move, keeping the bullish thesis unresolved.

Nov 25, 2025

ZM received a Outperform rating from Daniel Ives on Nov 25, 2025, aiming for 95. Momentum has favored the Buy call, with shares climbing from 95.46 to 95.46, rewarding those who trusted the recommendation.

Nov 24, 2025

On Nov 24, 2025, Daniel Ives published a Outperform outlook on VFS, with a target of 6. Market action contradicted the Buy thesis, as shares slipped to 3.01.

Nov 21, 2025

Daniel Ives on Nov 21, 2025 assigned ESTC a Outperform rating, with a price target of 90. The Buy call aligned well with market performance, producing a gain of 19.19%.

Nov 12, 2025

On Nov 12, 2025, Daniel Ives reaffirmed OKLO with a Outperform rating, targeting 150. Shares slid 64.13% despite the recommendation, highlighting downside risks.

Nov 11, 2025

TLS was rated Outperform by Daniel Ives on Nov 11, 2025, with a price objective of 10. This case shows how bullish projections can fail, with the stock now below 4.68.

Nov 10, 2025

On Nov 10, 2025, Daniel Ives initiated coverage on ZS with a Outperform rating and target of 350. The Buy call has yet to be validated as shares remain 186.52 away from the target.

Nov 07, 2025

Daniel Ives issued a Outperform recommendation for TSLA on Nov 07, 2025, price target set at 600. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Nov 06, 2025

On Nov 06, 2025, ALIT was evaluated by Daniel Ives, who gave a Outperform rating and target of 5. Investors saw limited payoff as shares fell short of the 5 target.

Nov 06, 2025

Daniel Ives rated CCSI as Outperform on Nov 06, 2025, setting a price target of 35. The call has proven timely, with shares rising 45.10% toward the price target of 35.

Oct 23, 2025

On Oct 23, 2025, PEGA was given a Outperform rating by Daniel Ives, with a target price of 75. Despite the Buy call, shares fell from 35.72 to 35.72, challenging the optimistic stance.

Oct 21, 2025

GM received a Outperform rating from Daniel Ives on Oct 21, 2025, aiming for 75. Momentum has favored the Buy call, with shares climbing from 86.12 to 86.12, rewarding those who trusted the recommendation.

Oct 16, 2025

Daniel Ives on Oct 16, 2025 assigned CRM a Outperform rating, with a price target of 375. The recommendation remains pending validation as shares consolidate around 243.

Sep 11, 2025

SOUN was rated Outperform by Daniel Ives on Sep 11, 2025, with a price objective of 16. This case shows how bullish projections can fail, with the stock now below 6.28.

Sep 11, 2025

On Sep 11, 2025, Daniel Ives initiated coverage on RBRK with a Outperform rating and target of 120. The stock’s climb of 14.15% since the call highlights the foresight in the rating.

Aug 27, 2025

Daniel Ives issued a Outperform recommendation for SERV on Aug 27, 2025, price target set at 15. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Aug 14, 2025

On Aug 14, 2025, XOS was evaluated by Daniel Ives, who gave a Outperform rating and target of 7. Investors saw limited payoff as shares fell short of the 7 target.

Aug 08, 2025

Daniel Ives rated OS as Outperform on Aug 08, 2025, setting a price target of 25. The call has proven timely, with shares rising 19.28% toward the price target of 25.

Aug 07, 2025

On Aug 07, 2025, FTNT was given a Outperform rating by Daniel Ives, with a target price of 100. The stock rallied 110.96% after the rating, narrowing the gap to the target of 100 and validating the bullish stance.

Aug 06, 2025

RIVN received a Outperform rating from Daniel Ives on Aug 06, 2025, aiming for 16. Momentum has favored the Buy call, with shares climbing from 16.05 to 16.05, rewarding those who trusted the recommendation.

Aug 06, 2025

On Aug 06, 2025, Daniel Ives published a Outperform outlook on QLYS, with a target of 155. Shares gained 23.97%, underscoring the accuracy of the bullish outlook toward 155.

Aug 05, 2025

Daniel Ives on Aug 05, 2025 assigned PLTR a Outperform rating, with a price target of 200. The recommendation remains pending validation as shares consolidate around 165.86.

Jul 31, 2025

TENB was rated Outperform by Daniel Ives on Jul 31, 2025, with a price objective of 42. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Jul 01, 2025

On Jul 01, 2025, Daniel Ives initiated coverage on PRGS with a Outperform rating and target of 75. The Buy call has yet to be validated as shares remain 34.39 away from the target.

Jun 25, 2025

Daniel Ives issued a Outperform recommendation for TMC on Jun 25, 2025, price target set at 11. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Jun 20, 2025

On Jun 20, 2025, NICE was evaluated by Daniel Ives, who gave a Outperform rating and target of 200. Investors saw limited payoff as shares fell short of the 200 target.

Mar 28, 2025

Daniel Ives rated VRNT as Outperform on Mar 28, 2025, setting a price target of 30. The call has proven timely, with shares rising 14.90% toward the price target of 30.

Mar 26, 2025

On Mar 26, 2025, HURN was given a Outperform rating by Daniel Ives, with a target price of 165. The stock traded sideways with a 4.86% move, keeping the bullish thesis unresolved.

Mar 12, 2025

On Mar 12, 2025, Daniel Ives published a Outperform outlook on PAY, with a target of 38. Shares gained 25.32%, underscoring the accuracy of the bullish outlook toward 38.

Dec 19, 2024

Daniel Ives on Dec 19, 2024 assigned SWI a Outperform rating, with a price target of 20. The Buy call aligned well with market performance, producing a gain of 29.48%.

Oct 09, 2024

On Oct 09, 2024, Daniel Ives reaffirmed CHKP with a Outperform rating, targeting 230. Shares slid 35.84% despite the recommendation, highlighting downside risks.

May 10, 2024

On May 10, 2024, Daniel Ives initiated coverage on ZD with a Outperform rating and target of 70. Neutral price movement of 3.99% leaves room for interpretation.